Overview A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma Status: Completed Trial end date: 2013-12-01 Target enrollment: Participant gender: Summary IPI-926 is an inhibitor of the hedgehog pathway. IPI-926 may improve therapeutic outcomes in patients with Chondrosarcoma. Phase: Phase 2 Details Lead Sponsor: Infinity Pharmaceuticals, Inc.